Lisata Therapeutics
LSTA
25 hedge funds and large institutions have $2.13M invested in Lisata Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
12% more capital invested
Capital invested by funds: $1.9M → $2.13M (+$226K)
0% less ownership
Funds ownership: 0.54% → 0.53% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
4% less funds holding
Funds holding: 26 → 25 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$94.2K |
| 2 |
STA
Summit Trail Advisors
New York
|
+$45.9K |
| 3 |
Renaissance Technologies
New York
|
+$29.8K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$4.24K |
| 5 |
BlackRock
New York
|
+$1.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$76.9K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$38K |
| 3 |
VF
Virtu Financial
New York
|
-$26K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$21K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8K |
LSTA Hedge Fund Activity: Q3 2019 in Review
25 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2019, worth a combined $2.13M — up 12% from $1.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LSTA and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $94.2K. The largest seller was Deutsche Bank, cutting an estimated $76.9K.
- 25 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2019, down from 26 in Q2 2019.
- Funds reported $2.13M of Lisata Therapeutics stock for Q3 2019, up 12% quarter-over-quarter.
- 4 funds opened new Lisata Therapeutics positions in Q3 2019 and 5 closed out, a net change of -1 holder.
- The largest Lisata Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $94.2K added.
- The largest Lisata Therapeutics seller in Q3 2019 was Deutsche Bank, an estimated $76.9K sold.
Based on aggregated 13F filings for Q3 2019.